A Lung Cancer Patient with Dyspnea: Diagnostic Difficulties during the COVID-19 Pandemic

Publication date: Available online 9 October 2020Source: Cancer CellAuthor(s): Melinda A. Pruis, Burhan Hussain, Marleen Bakker, Rogier A.S. Hoek, Jelle R. Miedema, Anne-Marie C. Dingemans, Marthe S. Paats
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 8 October 2020Source: The Annals of Thoracic SurgeryAuthor(s): Jean-Baptiste Leclère, Ludovic Fournel, Harry Etienne, Charbel Al Zreibi, Ilaria Onorati, Arnaud Roussel, Yves Castier, Emmanuel Martinod, Françoise Le Pimpec-Barthes, Marco Alifano, Jalal Assouad, Pierre Mordant, thoracic surgery units of Paris Public Hospitals.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Surgical resection is the standard-of-care approach for early-stage non-small cell lung cancer (NSCLC). Surgery is also considered an acceptable standard infit patients with oligometastatic lesions in the lungs. The COVID-19 pandemic has led to worldwide issues with access to operating room time, with patients and physicians facing uncertainty as to when surgical resection will be available, with likely delays of months. Further compounding this are concerns about increased risks of respiratory complications with lung cancer surgery during active phases of the pandemic. In this setting, many thoracic oncology teams are emb...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract As of April 17th, 2020, more than 2,190,010 COVID-19 cases with 147,010 deaths have been recorded worldwide. It has been suggested that a high mortality rate occurs in patients with severe disease and is associated with advanced age and underlying comorbidities, such as malignancies. To the best of our knowledge, no study has been conducted to evaluate chest CT features in patients with malignancy and concomitant COVID-19 infection. In fact, the imaging findings can be challenging and have not yet been fully understood in this setting. In this manuscript, we go over imaging findings in chest CT of patient...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Clin Imaging Source Type: research
FRIDAY, Sept. 18, 2020 -- More than half of patients have experienced changes in their lung cancer treatment plan as a result of the COVID-19 pandemic, according to a research letter published online Sept. 17 in JAMA Oncology. Arielle Elkrief,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
(JAMA Network) Changes in   lung cancer treatment during the COVID-19 pandemic were evaluated in this study.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Nearly 60% of people undergoing treatment for lung cancer experienced disruptions in care this spring because of the COVID-19 pandemic, according to an analysis published Thursday by JAMA Oncology.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Conclusions: Lung cancer patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, onset of ARDS, and high mortality rate. Although larger series are needed, no differences in mortality were found by type of cancer treatment. Measures to minimize the risk of SARS-CoV-2 infection remain key to protect lung cancer patients.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has killed many people worldwide since December 2019, and Iran has been among the most affected countries. In this retrospective study, we aimed to determine the prognostic factors associated with mortality in COVID-19 patients by analyzing 396 survived and 63 non-survived patients in Shahid Modarres Hospital, Tehran, Iran, from January 30th until April 5th, 2020. As the results, the BMI> 35 (p = 0.0003), lung cancer (p = 0.007), chronic kidney disease (p = 0.002), Immunocompromised condition (p = 0.003), and diabetes (p = 0.018) were more frequently obs...
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
This study uncovers the relationship between COVID-19 disease and lung cancer. We identified ACE2 and also its co-expressed proteins are the potential biomarker and therapy as the current COVID-19 disease and lung cancer. PMID: 32916258 [PubMed - as supplied by publisher]
Source: Genomics - Category: Genetics & Stem Cells Authors: Tags: Genomics Source Type: research
More News: Cancer | Cancer & Oncology | COVID-19 | Lung Cancer | Pandemics